Freedom of design, mass customisation, waste minimisation and the ability to manufacture complex structures, as well as fast prototyping, are the main benefits of additive manufacturing (AM) or 3D printing. A comprehensive review of the main 3D printing methods, materials and their development in trending applications was carried out. In particular, the revolutionary applications of AM in biomedical, aerospace, buildings and protective structures were discussed. The current state of materials development, including metal alloys, polymer composites, ceramics and concrete, was presented. In addition, this paper discussed the main processing challenges with void formation, anisotropic behaviour, the limitation of computer design and layer-by-layer appearance. Overall, this paper gives an overview of 3D printing, including a survey on its benefits and drawbacks as a benchmark for future research and development.

Additive manufacturing (3D printing): A review of materials, methods, applications and challenges

Early age mechanical behaviour of 3D printed concrete: Numerical modelling and experimental testing

Cementitious materials for construction-scale 3D printing: Laboratory testing of fresh printing mixture

Effect of surface moisture on inter-layer strength of 3D printed concrete

The application of additive manufacturing (AM) in construction has been increasingly studied in recent years. Large robotic arm- and gantry-systems have been created to print building parts using aggregate-based materials, metals, or polymers. Significant benefits of AM are the automation of the production process, a high degree of design freedom, and the resulting potential for optimization. However, the building components and 3D-printing processes need to be modeled appropriately. In this paper, the current state of AM in construction is reviewed. AM processes and systems as well as their application in research and construction projects are presented. Moreover, digital methods for planning 3D-printed building parts and AM processes are described.

Additive manufacturing in construction: A review on processes, applications, and digital planning methods

Background: Dendritic cell vaccination (DCV) strategies, thanks to a complex immune response, may flare tumor regression and improve patients’ long-term survival. This meta-analysis aims to assess the efficacy of DCV for newly diagnosed glioblastoma patients in clinical trials. Methods: The study databases, including PubMed, Web of Knowledge, Google Scholar, Scopus, and Cochrane, were searched by two blinded investigators considering eligible studies based on the following keywords: “glioblastoma multiforme”, “dendritic cell”, “vaccination”, “immunotherapy”, “immune system”, “immune response”, “chemotherapy”, “recurrence”, and “temozolomide”. Among the 157 screened, only 15 articles were eligible for the final analysis. Results: Regimens including DCV showed no effect on 6-month progression-free survival (PFS, HR = 1.385, 95% CI: 0.822–2.335, p = 0.673) or on 6-month overall survival (OS, HR = 1.408, 95% CI: 0.882–2.248, p = 0.754). In contrast, DCV led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid-term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in patients affected by a very poor prognosis.

/pdf/delayed-effect-of-dendritic-cells-vaccination-on-survival-in-26v3h4v1.pdf

Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis

A step-by-step procedure for performance-based testing of mixtures for construction-scale 3D printing is proposed. Workability of a fresh “printing mixture” is described in terms of print quality, shape stability, robustness, and printability window. To demonstrate the proposed procedure and test methods, an experimental program is carried out using four different mixtures. The experimental results are used as the basis for discussion and comparison of performance of developed mixtures for use in construction-scale 3D printing. Finally, perspectives on the future research areas as critical steps for advancement of construction-scale 3D printing are provided.

A Framework for Performance-Based Testing of Fresh Mixtures for Construction-Scale 3D Printing

BIM-integrated thermal analysis and building energy modeling in 3D-printed residential buildings

INTRODUCTION
This study aimed to evaluate chronic pain and fatigue in patients 12 months after hospitalization for Covid-19.


METHODS
We studied the COVID-19 patients discharged from Hospital, March 10 and April 20, 2020.


RESULTS
A total of 157 patients were included in this study. Forty-three patients (27.4%) complained of chronic fatigue and muscle weakness in the last six months. The visual analog fatigue scale (VAFS) score of 3.84 ± 1.48 was obtained. Forty patients (25.5%) were suspected of Chronic Fatigue Syndrome (CFS).Twenty-four patients (15.3%) had severe chronic pain or exacerbation of previous chronic pain, most of which were reported in the lower back (70.8%) and lower extremities (66.7%). Pain intensity had a mean score of 2.33 ± 0.87 and was mainly described as "muscle cramps," "persistent dull pain," and "boring and numbing." In women, chronic pain and fatigue, extended hospital stays, ICU admission, and depressed mood were common than in men.For these pain and fatigue, 37% used nonsteroidal anti-inflammatory drugs, and 16.3% used antidepressants. Only one person had applied for physiotherapy, and none of the patients had received psychotherapy.


CONCLUSION
Fatigue and chronic pain in patients recovering from COVID-19 are common complications, even after 12 months of illness.

The incidence and characteristics of chronic pain and fatigue after 12 months later admitting with COVID-19; The Post- COVID 19 syndrome.

Simple Summary Adequate embryo-maternal communication is essential for a successful pregnancy. In the dog, this interaction is intimately associated with maternal stroma-derived decidual cells, the only cell population in the canine placenta expressing the nuclear progesterone receptor (PGR) and, therefore, sensitive to the circulating progesterone levels. Prepartum decrease of progesterone or clinical application of PGR blockers (antigestagens, e.g., aglepristone and mifepristone) induce placental release of luteolytic factors and terminate pregnancy. However, the importance of progesterone for decidual cells functionality has not been fully elucidated. Therefore, we investigated the effects of PGR blockers on the expression of markers of decidualization and cellular viability, as well as on epithelial and mesenchymal factors in in vitro decidualized dog uterine stromal (DUS) cells. Decidualization increased the expression of the respective markers, including factors involved in cell growth and prostaglandin synthesis. Their expression was suppressed by the application of antigestagens. Additionally, the expression of factors involved in tissue remodeling and cell-cell communication was increased, and antiproliferative and proapoptotic effects were induced in decidualized cells. Altogether, progesterone signaling appears to be crucial for modulating decidual cells physiology and biological activity, and thus for the maintenance of pregnancy. Abstract Feto-maternal communication in the dog involves the differentiation of stromal cells into decidual cells. As the only placental cells expressing the nuclear progesterone (P4) receptor (PGR), decidual cells play crucial roles in the maintenance and termination of pregnancy. Accordingly, to investigate possible PGR-mediated mechanisms in canine decidual cells, in vitro decidualized dog uterine stromal (DUS) cells were treated with functional PGR-blockers, mifepristone and aglepristone. Effects on decidualization markers, epithelial and mesenchymal factors, and markers of cellular viability were assessed. Decidualization increased the expression of PTGES, PGR, IGF1, and PRLR, along with ECM1, COL4 and CX43, but downregulated IGF2. DUS cells retained their mesenchymal character, and the expression of COL4 indicated the mesenchymal-epithelial transformation. Antigestagen treatment decreased the availability of PTGES, PRLR, IGF1 and PGR. Furthermore, antigestagens decreased the mRNA and protein expression of CX43, and transcriptional levels of ECM1 and COL4. Additionally, antigestagens increased levels of activated-CASP3 (a proapoptotic factor), associated with lowered levels of PCNA (a proliferation marker). These data reveal important aspects of the functional involvement of PGR in canine decidual cells, regarding the expression of decidualization markers and acquisition of epithelial-like characteristics. Some of these mechanisms may be crucial for the maintenance and/or termination of canine pregnancy.

/pdf/antigestagens-mediate-the-expression-of-decidualization-pitvmylk.pdf

Antigestagens Mediate the Expression of Decidualization Markers, Extracellular Matrix Factors and Connexin 43 in Decidualized Dog Uterine Stromal (DUS) Cells

Ali Kazemian

Papers

Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis

A Framework for Performance-Based Testing of Fresh Mixtures for Construction-Scale 3D Printing

BIM-integrated thermal analysis and building energy modeling in 3D-printed residential buildings

The incidence and characteristics of chronic pain and fatigue after 12 months later admitting with COVID-19; The Post- COVID 19 syndrome.

Antigestagens Mediate the Expression of Decidualization Markers, Extracellular Matrix Factors and Connexin 43 in Decidualized Dog Uterine Stromal (DUS) Cells